We are enclosing herewith copy of Annual Report for the financial year ended 31st March 2026.

Krebs Biochemicals & Industries Limited CIN : L24110AP1991PLC103912 4th September 2026 To, To, BSE Limited National Stock Exchange of India Ltd P J Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex, Fort, Mumbai- 400001. Bandra(E), Mumbai- 400051. Scrip Code : 524518 Scrip Code : KREBSBIO Dear Sir / Madam, Sub: Annual Report 2025-26 We are enclosing herewith copy of Annual Report for the financial year ended 31st March 2026 for your perusal and record. Kindly acknowledge the receipt. Thanking you, Yours Faithfully For Krebs Biochemicals & Industries Limited Rakesh R. Kalbate Company Secretary & Compliance Officer ACS 66666 Encl.: a/a. Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Tel : 040-66808040 Website- www.krebsbiochem.com E-mail com_sec@krebsbiochem.com Annual Report 2 0 2 5 - 2 6 Krebs Biochemicals & Industries Limited Five Years’ Highlight (` In Lakhs) Particluars 2021-22 2022-23 2023-24 2024-25 2025-26 Total Income 6,085.89 5,275.46 5,087.28 4,402.08 2,575.79 Profit / (Loss) Before Tax (4,452.68) (2,469.19) (1,972.84) (2,692.40) (1,693.31) Profit /(Loss) After Tax (4,452.68) (2,469.19) (1,972.84) (2,693.93) (1,693.31) Share Capital 2,156.06 2,156.06 2,156.06 2,156.06 2,156.06 Reserves & Surplus (9,665.38) (12,102.29) (14,077.73) (16,779.94) (18,431.53) Net Worth (7,509.32) (9,946.23) (11,921.67) (14,623.88) (16,275.47) Earnings Per Share (`) (20.81) (11.30) (9.16) (12.49) (7.85) Book Value Per Share (`) (34.83) (46.13) (55.29) (67.83) (75.49) CONTENTS Corporate Information 2 Notice 3 Directors’ Report 21 Secretarial Audit Report 30 Report on Corporate Governance 37 Management Discussion and Analysis 56 Independent Auditors’ Report 59 Balance Sheet 70 Statement of Profit and Loss 71 Cash Flow Statement 72 34th Annual Report 2025-26 Krebs Biochemicals & Industries Limited BOARD OF DIRECTORS REGISTERED OFFICE Dr. R T Ravi Krebs Biochemicals & Industries Limited Chairman / Non-Executive Director Kothapalli (V), Kasimkota (M), Anakapalli (D), (DIN - 00272977) Andhra Pradesh – 531031. Tel: +91 - 9121144984 Mr. Manish Kumar Jain Email : com_sec@krebsbiochem.com Managing Director & CEO Website: www.krebsbiochem.com (DIN - 06477976) CIN: L24110AP1991PLC103912 Mr. P K Bhattacharyya PLANT LOCATIONS Non-Executive Director (DIN - 07131152) Unit I: Regadichelika (V), Kodavalur (M), Nellore (D), Andhra Pradesh–524316. Mr. Avinash Ravi Non-Executive Director Unit II: Kothapalli (V), Kasimkota (M), Anakapalli, (DIN - 01616152) Vishakapatnam (D), Andhra Pradesh – 531031. Mr. P M Kathariya STATUTORY AUDITORS Independent Director M/s. Bhavani & Co. (DIN - 00281395) Chartered Accountants (FRN. 012139S) Ms. Dipti Shah Plot No. 48, Flat No. 201 , 2nd Floor, MICASA, Independent Director Phase - I, Kavuri Hills, Hyderabad – 500033. (DIN - 07995542) SECRETARIAL AUDITORS Mr. Satya Prakash Chigurupati DSMR & Associates Independent Director Company Secretaries, (DIN - 00721318) # 6-3-668/10/42, Plot No. 42, 2nd Floor, Durga Nagar Colony, Punjagutta, Mr. Sumanth Karlapudi Hyderabad - 500082 Independent Director (DIN - 09188185) REGISTRARS AND SHARE TRANSFER AGENTS KEY MANAGERIAL PERSONNELS KFin Technologies Ltd. Mr. Ritesh Jain Plot No. 31 & 32, Selenium Tower B, Financial District, Chief Financial Officer Nanakram Guda, Gachibowli, Hyderabad- 500032. Ph: 040-67161605 Fax: 040 – 67161500 Mr. Rakesh R Kalbate Website: www.kfintech.com Company Secretary & Compliance Officer Email: einward.ris@kfintech.com 34th Annual Report 2025-26 Notice Notice Notice is hereby given that the 34th Annual General Meeting of the members of Krebs Biochemicals & Industries Limited will be held on Tuesday, 29th September 2026 at 11:30 AM through Video Conferencing / Other Audio Visual Means (VC/OAVM) to transact the following business: ORDINARY BUSINESS: 1. To receive, consider, approve and adopt the Audited Balance Sheet, the Statement of Profit & Loss and Cash Flow Statement for the financial year ended 31st March 2026 together with the Notes attached thereto along with the Reports of Auditors and Directors thereon. 2. To appoint a director in place of Dr. R T Ravi (DIN - 00272977), who retires by rotation and being eligible, offers himself for re-appointment. 3. To appoint a director in place of Mr. Manish Kumar Jain (DIN - 06477976), who retires by rotation and being eligible, offers himself for re-appointment. SPECIAL BUSINESS: 4. Approval for Related Party Transactions with Ipca Laboratories Limited To consider and if thought fit, to pass, the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the Regulation 23(4) read with Regulation 2(1)(zc) and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”), the applicable provisions of the Companies Act, 2013 (“Act”) read with related rules, other applicable laws / statutory provisions, if any, each as amended from time to time, (including any statutory modification, amendment or reenactment thereof for the time being in force) and the Company’s policy on Related Party transaction(s), and based on the recommendation of the Audit Committee and Board of Directors, approval of Shareholders of the Company be and is hereby accorded to the Board of Directors of the Company to enter into contract(s)/ arrangement(s)/ transaction(s) with Ipca Laboratories Limited, a promoter company and related party within the meaning of Section 2(76) of the Act and Regulation 2(1)(zb) of the Listing Regulations, for a) Purchase/ sale of materials, capital goods, plant & machineries, packaging materials; b) receiving advances; c) lease and licenses arrangement d) accepting loans/inter-corporate deposits accordance with the provisions of Companies Act; e) transfer of any resources, services or obligations to meet company’s business objectives/ requirements; f) conversion of materials on job work basis, loan license manufacturing arrangement, contract manufacturing services, etc. (“Related Party Transactions”) on such terms and conditions as the Board of Directors may deem fit, up to a maximum aggregate value of ` 120 Crore for any given financial year including financial year 2026-27, provided that the said contract(s)/ arrangement(s)/ transaction(s) so carried out shall be at an arm’s length basis and in the ordinary course of the business of the Company. RESOLVED FURTHER THAT the Board, be and is hereby authorised to delegate all or any of the powers herein conferred under this resolution to any Committee of Directors of the Company or any Director(s) or Chief Financial Officer, Company Secretary or any other Officer(s) / Authorised Representative(s) of the Company and to do all such acts, deeds, matters and things as it may deem fit in its absolute discretion and to take all such steps as may be required in this connection including finalizing and executing necessary contract(s), arrangement(s), agreement(s) and such other documents as may be required, seeking all necessary approvals to give effect to this resolution, and to resolve all such issues, questions, difficulties or doubts whatsoever that may arise in this regard and all action(s) for and on behalf of the Company in connection with any matter referred to or contemplated in this resolution, be and are hereby approved, ratified and confirmed in all respects.” 34th Annual Report 2025-26 Krebs Biochemicals & Industries Limited 5. To ratify the remuneration payable to the Cost Auditors To consider and if thought fit, to pass, the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 148(3) and such other applicable provisions, if any, of the Companies Act, 2013 read with rules made thereunder, M/s. Bojanapalli & Associates, Cost Accountants (Firm Registration No. 100849) who have been appointed as the Cost Auditors of the Company to conduct the audit of the cost r [Showing first 8,000 characters — download PDF for full document]